A dog’s diet can influence the severity and course of canine atopic dermatitis (AD). Supplementation with fatty acids can alter the lipid composition of the epidermis and augment a compromised cutaneous barrier, thus preventing AD in genetically susceptible dogs. The same principles apply to humans. Diet and season can influence the severity and course of AD in dogs. Atopy-related symptoms are often more severe in spring and fall, so it’s best to start the treatment process early. In the early stages, the signs of canine atopic dermatitis may be mild or severe, and it is important to consult a veterinarian if the dog exhibits symptoms. Food allergies in dogs are most common in fleas and foods, although they can be triggered by normal bacterial flora as well. While the condition can be frustrating, it can be managed with multimodal treatment.
Canine atopic dermatitis can also be caused by allergies to certain foods. Many pet owners don’t suspect their dogs are allergic to their food. However, animals can develop allergies over time. By choosing the right foods for their dog, they can avoid the most common allergens.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/4886
Increasing healthcare expenditure for pets and treatment of canine atopic dermatitis are expected to drive the canine atopic dermatitis treatment drugs market growth over the forecast period. For instance, according to American Pet Products Association (APPA) report of March 2019, pet care spending in 2018 reached US$ 72.5 billion compared to US$ 69.5 billion in 2017, an increase of over 4%.
Moreover, key players are focused on drug development, approvals from regulatory bodies, and commercialization of innovative therapeutics for canine atopic dermatitis. Thus, increasing product approval and agreements are expected to significantly drive growth of the global canine atopic dermatitis treatment drugs market over the forecast period.
For instance, in December 2020, Kindred Biosciences, Inc., a biopharmaceutical organization which focuses on improving the lives of animals, announced an agreement permitting Elanco Animal Health, a world leader in developing innovative products and solutions that enhance animal health, incorporated exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus. The organization also has the rights to refuse to manufacture certain antibody products of Elanco’s, as per stated in the agreement.
Canine Atopic Dermatitis Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 260 million cases and 5.2 million deaths due to Coronavirus (COVID-19) were reported up till November 29, 2021, across the globe.
The cats, dogs and other types of animals are at risk of obtaining the virus, as per the data of centers for disease control and prevention. The study is still further continued regarding the connection between human and animal transmission of virus. Moreover, the government is looking after all the services that can help in supplying the medicines. For instance, the European Medicines Agency provided direction for the organization who are responsible for veterinary medicines, firstly to overcome the challenges faced in between the pandemic.
Many companies are focusing on research and development of new drugs for treating canine atopic dermatitis, which is expected to boost the growth of the global canine atopic dermatitis treatment drugs market over the forecast period. For instance, Kindred Biosciences Inc., is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets, has a robust pipeline of preventive drugs for dogs, cats, and horses, in which three drugs are undergoing clinical trials and are expected to be novel immunotherapies for treatment of canine atopic dermatitis.
Key Takeaways of the Canine Atopic Dermatitis Treatment Drugs Market:
- The global canine atopic dermatitis treatment drugs market is expected to witness a CAGR of 16.5% during the forecast period (2021–2028), owing to the rising healthcare expenditure for pets and treatment of canine atopic dermatitis
- Among drug class, the Janus kinase inhibitors segment is expected to account for major revenue share in 2028, owing to its better survival rates and rising sales. For instance, in 2018, APOQUEL generated a revenue of US$ 464 million in sales. APOQUEL is the largest revenue generating product of Zoetis Inc., a global animal health company.
- Major players operating in the global canine atopic dermatitis treatment drugs market include Zoetis Inc., Elanco Animal Health Incorporated, Virbac, Kindred Biosciences, Inc., Nippon Zenyaku Kogyo Co., Ltd. (ZENOAQ), Bioiberica S.A.U, Dechra Pharmaceuticals PLC, and Toray Industries, Inc.
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/4886
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Canine Atopic Dermatitis Treatment Drugs Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Canine Atopic Dermatitis Treatment Drugs Industry Impact
Chapter 2 Global Canine Atopic Dermatitis Treatment Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Canine Atopic Dermatitis Treatment Drugs (Volume and Value) by Type
2.3 Global Canine Atopic Dermatitis Treatment Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Canine Atopic Dermatitis Treatment Drugs Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Canine Atopic Dermatitis Treatment Drugs Market Analysis
Chapter 6 East Asia Canine Atopic Dermatitis Treatment Drugs Market Analysis
Chapter 7 Europe Canine Atopic Dermatitis Treatment Drugs Market Analysis
Chapter 8 South Asia Canine Atopic Dermatitis Treatment Drugs Market Analysis
Chapter 9 Southeast Asia Canine Atopic Dermatitis Treatment Drugs Market Analysis
Chapter 10 Middle East Canine Atopic Dermatitis Treatment Drugs Market Analysis
Chapter 11 Africa Canine Atopic Dermatitis Treatment Drugs Market Analysis
Chapter 12 Oceania Canine Atopic Dermatitis Treatment Drugs Market Analysis
Chapter 13 South America Canine Atopic Dermatitis Treatment Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Canine Atopic Dermatitis Treatment Drugs Business
Chapter 15 Global Canine Atopic Dermatitis Treatment Drugs Market Forecast (2022-2028)
Chapter 16 Conclusions
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/4886
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027